Tacrolimus Ointment (Protopic)
Revolutionary steroid-free topical immunomodulator selectively suppressing T-cells
About This Treatment
Tacrolimus ointment (Protopic 0.1%/0.03%) is an insurance-covered topical calcineurin inhibitor. Selectively suppresses T-cell activation without causing steroid side effects (skin atrophy, telangiectasia). Particularly useful for facial/neck atopic dermatitis. First-choice for steroid-problematic areas (face, eyelids, groin). Also used for vitiligo in aesthetic dermatology.
Mechanism of Action
Tacrolimus binds cytoplasmic FKBP-12, and the complex inhibits calcineurin (calcium/calmodulin-dependent phosphatase). This prevents NFAT dephosphorylation/nuclear translocation, suppressing T-cell cytokine production (IL-2, IL-4, IL-5, IFN-γ). Unlike steroids, does not inhibit collagen synthesis - no skin atrophy. Large molecular weight (822Da) limits absorption to barrier-damaged inflamed skin only.
Indications
Expected Results
Significant inflammation improvement at 1-2 weeks. Clinical trials: >67% of patients achieve >50% improvement. Rapid reduction of facial erythema and pruritus. No skin atrophy or telangiectasia with long-term use (>1 year). Proactive therapy (twice weekly maintenance) significantly reduces relapse.
Clinical Evidence
Risks & Side Effects
Initial burning/stinging at application site (40-50%) usually subsides in days to 1 week. Theoretical infection risk from immunosuppression (HSV). FDA black box warning (lymphoma risk) but no causation established after 20+ years of post-marketing surveillance. Alcohol-induced facial flushing may occur. Sun protection recommended. Only 0.03% for children under 2.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition